Erlotinib

7 trials 1 recruiting LOncology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

5 Completed trials

4 Sponsors

6 Countries

Phase III

Phase II

Phase III: 3 Phase II: 4

Oversight events:

1 serious breach across 1 trial

View oversight register →

Sponsors using this IMP

Eli Lilly & Co. 3 Region Hovedstaden 2 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 IRCCS Istituto Nazionale Tumori Fondazione Pascale 1

All trials

7 total

Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with… Ended

2024-516843-15-00 Phase III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Ended

2023-506779-82-00 Phase III 1 country Eli Lilly & Co.
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Phase II 1 country Region Hovedstaden
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic… Ended

2024-514269-20-00 Phase III 1 country Eli Lilly & Co.
A study, in which patients with late-stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug er… Ended

2024-514268-18-00 Phase II 2 countries Eli Lilly & Co.

Showing 1–7 of 7 trials

← All drugs A–Z